Alzheimer's Drug Aduhelm - Search Videos

First new drug for Alzheimer's in 20 years approved by FDA

First new drug for Alzheimer's in 20 years approved by FDA

'Terrible dilemma': Toobin on FDA's Alzheimer treatment approval

'Terrible dilemma': Toobin on FDA's Alzheimer treatment approval

FDA approves an Alzheimers drug

FDA approves an Alzheimers drug

FDA approves controversial Alzheimer's drug

FDA approves controversial Alzheimer's drug

Medicare to Review Coverage for New Alzheimer’s Drug Aduhelm

Medicare to Review Coverage for New Alzheimer’s Drug Aduhelm

Alzheimer's drug Aduhelm, priced at $56,000 a year, is a key factor driving up Medicare premiums

Alzheimer's drug Aduhelm, priced at $56,000 a year, is a key factor drivi…

FDA and Biogen's push to accelerate approval of Alzheimer's drug

FDA and Biogen's push to accelerate approval of Alzheimer'…

FDA revises prescribing instructions for new Alzheimer’s d…

FDA approves new treatment for Alzheimer’s disease

ABC NewsDr. Deepak Ramanathan,Sony Salzman

Fox Business Flash top headlines for July 16

Fox BusinessAlexandria Hein

A new Alzheimer's drug brings hope, controversy

CBS NewsAimee Picchi

Biden’s Alzheimer’s Lapse

WSJThe Editorial Board

The FDA’s big gamble on the new Alzheimer’s drug

theconversation.com

FDA approves Biogen's Alzheimer's medication: How to invest

Fox BusinessFox Business

Aducanumab (Aduhelm) For Alzheimer’s Disease » Departmen…

Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half

Opinion | Sandbagging an Alzheimer’s Treatment

BioVie: Treating Alzheimer's, Parkinson's potentially reversing t…

Fox BusinessJulia Musto

Biogen plans to shut down its controversial Alzheimer’s drug Ad…

torontosunAssociated Press,Tom Murphy

Aduhelm: FDA head calls for review of Alzheimer's drug

New Alzheimer’s Drug: What Doctors Want You to Know About …

FDA approves Alzheimer’s drug Aduhelm, but concerns raised abo…

The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug

Opinion | Requiem for an Alzheimer’s Drug

Medicare limits coverage of $28,000-a-year Alzheimer's drug

Unpacking the controversy over Aduhelm, newest approved Alzhei…

tallahassee.com

Opinion | Biogen’s CEO Becomes a Political Sacrifice

wsj.comAllysia Finley

Medicare limits coverage of $28,000-a-year Alzheimer's drug

Mobile health services provider DocGo goes public via SPAC

Fox BusinessLucas Manfredi

Hope and anxiety surround new Alzheimer’s drug lecanemab

CBCLauran Neergaard

See more videos